Risk of pacemaker implantation after radiotherapy for breast cancer: A study based on French nationwide health care database sample. (February 2022)

• Record Type: Journal Article
• Authors: Errahmani, M.Y.; Thariat, J.; Ferrières, J.; Panh, L.; Locquet, M.; Lapeyre-Mestre, M.; Guernec, G.; Bernier, M.O.; Boveda, S.; Jacob, S.
• Is Part Of: IJC heart & vasculature. Volume 38(2022)
• Publication Date: 2022-02
• Subjects: Breast Cancer -- Radiotherapy -- Cardiac complications -- Pacemaker -- French national health insurance database; Cardiovascular system -- Diseases -- Periodicals; Cardiovascular system -- Pathophysiology -- Periodicals; 616.1005
• DOI: 10.1016/j.ijcha.2021.100936
• Languages: English
• ISSNs: 2352-9067

Abstract

Abstract: Background: Among cardiac complications of breast cancer radiotherapy (BC RT), there are very limited data on arrhythmia and conduction disorders, in particular severe cases requiring permanent pacemaker implantation (PPMI). Therefore, this exploratory study aimed to evaluate the risk of PPMI for BC patients treated with RT, compared with the general population and with BC patients not treated with RT. Methods: The study was performed on a 1/97 representative sample of the French health care database (EGB database). Adult women with a first BC treated with or without RT between 2008 and 2016 were included, followed until 2018, and de novo PPMI were identified. We compared the PPMI incidence in BC cohort relative to the general population with standardized incidence ratio (SIR) and evaluated the risk of PPMI in RT patients compared to patients without RT with a competing risk survival analysis. Results: A total of 3853 BCE patients were included. Among BC patients treated with RT, 28 PPMI cases were observed compared with 13 expected cases, corresponding to a SIR of 2.18 [95% CI: 1.45–3.06]. For BC patients not treated with RT, the SIR was 1.01 [95% CI: 0.40–1.90]. Patients treated with RT showed a borderline significant higher risk of PPMI compared with those not treated with RT (subdistribution Hazard Ratio = 2.08, 95% CI 0.87–4.97, p = 0.09). Conclusions: Our exploratory findings indicate that, over the last decade in France, BC patients treated with RT appeared to be at higher risk of PPMI than general population. Further studies are needed to expand on this topic.